Office of Research & Development |
|
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01BX004270-01 |
| Title: | Design of Novel Non-catalytic Substrate-Selective p38 MAPK Inhibitor to Treat ARDS |
| Principal Investigator: | Jeffrey D. Hasday |
| Location: | Baltimore, MD |
| Congressional District Code: | 7 |
| Research Service: | Biomedical Laboratory R&D |
| Project Period: | July 2018 - June 2022 |
| FY 2021 Funding Amount: | $123,750 |
| Total Award Amount (all years): |
$491,050 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Acute Respiratory Distress Syndrome (ARDS) is a complication of serious infections and trauma and an important source of morbidity and mortality in Veterans and the general population. Despite improvements in supportive care, no pharmaceutical therapies have been developed and mortality remains over 40%. Although preclinical studies support pharmacologic inhibition of p38 mitogen-activated protein kinase (MAPK) to treat a range of inflammatory diseases, including ARDS, the currently available p3... |